Arteaus Therapeutics sells royalty interest in Emgality for $260 mln
Arteaus Therapeutics, a biotech development company co-founded by Atlas Venture and OrbiMed, has sold its royalty interest in Eli Lilly and Company's Emgality to Royalty Pharma for $260 million. Morgan Stanley was sole structuring agent on the monetization. Wilmer Cutler Pickering Hale and Dorr LLP served as legal adviser to Arteaus while Jones Day and Maiwald served as legal advisers to Royalty Pharma.
1 April 2019•3 mins read
